Search
Now showing items 1-10 of 13
The role of metabolomics in tuberculosis treatment research
(Future Medicine, 2017)
Despite the fact that tuberculosis (TB) is a curable disease, it still results in approximately 1.8 million deaths annually. Various inadequacies in the current TB treatment strategies are major contributors to this high ...
New insights into the survival mechanisms of rifampicin-resistant Mycobacterium tuberculosis
(Oxford Univ Press, 2016)
Objectives: Rifampicin is considered the most important antibiotic for treating TB, but unfortunately Mycobacterium tuberculosis is rapidly developing resistance to this drug. Despite the fervent research efforts to date, ...
Urinary metabolite markers characterizing tuberculosis treatment failure
(Springer, 2017)
Background
Considering that approximately 15% of the nine million new tuberculosis (TB) cases reported per annum are not treated successfully, new, distinctive and specific biomarkers are needed to better characterize the ...
Predicting tuberculosis treatment outcome using metabolomics
(Future Medicine, 2017)
Aim: Predicting a poor treatment outcome would offer significant benefits for patient care and for new drug development. Materials, methods & results: Urine samples from tuberculosis-positive patients with a successful and ...
The application of metabolomics toward pulmonary tuberculosis research
(Elsevier, 2019)
In the quest to identify novel biomarkers for pulmonary tuberculosis (TB), high-throughput systems biology approaches such as metabolomics has become increasingly widespread. Such biomarkers have not only successfully been ...
Elucidating the antimicrobial mechanisms of colistin sulfate on Mycobacterium tuberculosis using metabolomics
(Elsevier, 2018)
Considering the disadvantageous of first line anti-tuberculosis (TB) drugs, including poor patient adherence, drug side effects, the long treatment duration and rapidly increasing microbe resistance, alternative treatment ...
Metabolomics of colistin methanesulfonate treated Mycobacterium tuberculosis
(Elsevier, 2018)
Over the past 5 years, there has been a renewed interest in finding new compounds with anti-TB action. Colistin methanesulfonate or polymyxin E, is a possible anti-TB drug candidate, which may in future be used either alone ...
A comparison of two extraction methods for differentiating and characterising various Mycobacterium species and Pseudomonas aeruginosa using GC-MS metabolomics
(Academic Journals, 2012)
We investigated the capacity of a metabolomics research approach to characterise and differentiate between various infectious Mycobacterium species and Pseudomonas aeruginosa, and compared two extraction procedures; 1) ...
New sputum metabolite markers implicating adaptations of the host to Mycobacterium tuberculosis, and vice versa
(Elsevier, 2013)
In this study, a metabolomics research approach was used to identify new tuberculosis (TB) markers from
sputum, in an attempt to better characterise the disease as well as the metabolic response of the host to
Mycobacterium ...
TB or not TB? Improving the understanding and diagnosis of tuberculosis through metabolomics
(Future Medicine, 2016)
“
...metabolomics has resulted in an exponential increase in the
number of newly identified tuberculosis biomarkers, which has not
only shed light on previously unknown disease mechanisms, but could
potentially ...